PLx Pharma Winddown (PLXPQ) 12 Nov 212021 Q3 Earnings call transcript

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the PLx Pharma Third Quarter 2021 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded. now Lisa hand Wilson would to conference I speaker, your with Instructions] like the to over [Operator Investor Relations. ahead. go Please

Thank on Officer Executive today’s Officer; Pharma’s of PLx are Natasha This PLx. Investor Welcome Rita and earnings call for Carmen. Chief President Relations me call. Wilson, is O’Connor, QX With PLx. and Giordano, results Lisa you, XXXX to Chief Financial

the access the at webcast Investors through section also call website of can You plxpharma.com. this PLx the of

based this SEC. PLx including and future those noted morning materially guarantees results as performance would involve defined forward-looking may are like performance. These with Such by made from be company’s filings I the uncertainties, statements. as The regarding remind everyone call as Actual of these in on may Before except forward-looking webcast specifically express statements required website, to intent be days started, disclaims statements, obligation forward-looking we of and risks expectation, or future to and intent our will Private are to by that any information not Pharma’s PLx in on today projected anticipation XX the our differ on forward-looking available that update statements for press archived our Reform release available Securities law. and the any management get future those events considered or issued conference statements Litigation today’s statements Act. forward-looking the projection, a belief, forecast, plxpharma.com.

PLx reference press that, company’s was to maybe I so with XX, the on held over the announcements Giordano. archived of replay this SEC Natasha And For XXXX. may call releases the PLx’s or please related made November who filings. discussed, those to the recorded turn recent CEO, to have will topics benefit call most and the Since then, listening and webcast,

today. Thank you thank for us joining you, Lisa. Good morning, everyone, and

the by Consumers are engine many purchases, frequent highlights search consolidating design, being importance displays has By the since promote sales the of of as phase behavior our has retail VAZALORE the Online our stores shortages of ecommerce level as shelves well outstanding it sites wide part adoption shopping also of initial as market store been from store. team availability expanding to available and important was XX,XXX completed market, marketplace attention VAZALORE. and product and but major product convenient successfully in store. platform. management larger seasoned and trade in of strategy VAZALORE challenges to proud the as We retail shopping has in chain up stocking are changed VAZALORE simply strong to successfully and distribution baskets nationwide, a have labor sales placed such curbside launch placement are consumer the Digital pivoted in remained well able the an in This global to purchasing buy a phase they to grabbing This whenever, however have shopping wherever, prominently consumers’ even extensive ecommerce making further partnerships as to COVID. the been pickup. than is and This shop. simply incredibly supported supply on bring more retail of our our online services make and consumers pickup sites. on of less achieving in

available content sites. on Our is VAZALORE enhanced ecommerce major

including third of first VAZALORE will to share CFO information provide key next call Rita? on Rita Before and I our Head of phase drivers our over who Supply performance. will the the results, quarter turn Chain, of Manufacturing launch, I and feedback our further market and sales the O’Connor,

of the drivers To orders our across on Today, and stock third of provide morning, including the initial Natasha, sales third and reflecting in good I will perspective key retail recorded some our begin, quarter, product performance. you, quarter channels. our U.S. VAZALORE of top-tier we first-ever everyone. mass food, Thank results drug,

VAZALORE plan commercial well X is for underway. Phase Our

so factor in support given XXX success stores labor product SKUs a extensive determination execution shifts and retailers an to the and supply in own, is seasoned achieving proud the such our three displays XX,XXX management U.S. SKUs, and stocking level prominently global us sites. testament as in behavior, early more one including trade the than its ecommerce of store. but dose, well challenges the SKU and and ongoing are of elsewhere chain this milligram important placed XX On We all are this in of is team’s retail the of and of and as Many for two distribution distribution impressive, the dose shopping team. consumer resilience milligram

in As a will retailer. we received for that when means recognize is reminder, which we basically with by the account revenue accordance ASCXXX, product revenue

led is pay growing revenue both the prompt and performance SKUs, initial retail few returns, the and weeks sales at I redemptions the provisions Net past building mentioned. the sales third for data promotional consumers. allowances net both by retailer milligram doses. milligram the gross $X.X those were consumption net including double-digits quarter. in with We VAZALORE shows reflecting weekly which count programs, will million, milligram shipments of just netted to to retailers represent and dose, by various XXX also total for the the record nearly Early discounts sales Total XX XX were quarter product coupon reductions XX product XX by in two-thirds

into in are acceleration VAZALORE fourth quarter on in plans, the As a elaborate on Once sales these completed we now phase Natasha and focuses will into XXXX. of we activities activities the initial which our moving Phase X, moment. distribution plan,

shift the New the in-store expect retails down trade their Month Health Year by holiday Heart As rush, brand XXXX early to begin consumer typically planned of typical growing several focus to activities as in over products demand year up mega by to initial with VAZALORE end, centered work with previous our experience launches, we reorder Then stock around to promotional weeks. partners promotional and the several February. meaningfully next they inventory our in activities, in driven

the to cost gross quarter. storage include said inbound, payments packagers, of we blended costs margin to to consistent shipment, and smaller batch because cost raw than the with although sales processing, milligram, materials is actual contract fees product plus XXXX. when of in manufacturing our center see milligram bottles. same at proportionately have provide in our higher This larger cost count margin resulted we a Moving the expand gross expected our they distribution the dose milligram University for improve paid Midwest. associated order to of in as and and Texas manufacturing outbound for completion XXX product an the as Royalty also margins, We of third cost Currently, much XX% our in capacity with lower sales margin handling are dose, of of milligram previously, our sizes, have price sizes, the the batch XX late both XX to the XX opportunity of XXX particularly list sales.

trial consumers the XX from trade lower to accelerates XX size pack. We count XX the milligram that launch up product the count also larger margin expect that will

on Moving expenses. to operating

clinical reflecting will manufacturing-related milligram to expenses clinical included the $X.X milligram bioequivalent Our trials, for detail also spending XX% which million, Natasha VAZALORE. further discuss third activities XX study. research and on quarter increased XXX XXXX pre-commercial trial, and for periods include Both in development was VAZALORE XXXX spending

approximately totaled Selling, the VAZALORE PLxGuard $X million development as protected, year to marketing the Our due and underway. capacity, further activities R&D technology. prior support to and XXXX the our expenses as and quarter manufacturing well for include in expense primarily of $XX investments continue to to remainder patent using extensive administrative million of expanding will XXXX period, compared in launch work feasibility products

is specialty that means more among and and is XX% trials reaching about In nearly XXX is audience on The deployed fully of consumers, of Our impressions launched in VAZALORE a ask professionals message July. base target force end frequency. October, the motivate doctors field to among VAZALORE. drive our television we awareness from August, audience. integrated and nationwide. high awareness our This delivered end our professionals our resonating for campaign consumers target driving first cardiovascular of and media than awareness VAZALORE campaign of healthcare positive. the was Early building national focused generate or this of healthcare to team driving with million very TV success feedback consumers has and XX campaign consumers our Through million adoption

the of Feedback to all, we the as in GAAP patients the launch from our goal be In a Our fourth roll to continue our total of the phase are throughout operating XX% of out and the XXXX quarter $XX basis, and third halo compared a in or is basic by or diluted in $X.XX advertisement diluted commercials period. expected, traffic ask our form a website quarter, the year. million net in share also of we the to Aspirin reported field now basic as doctor target quarter, the expenses having reaching expect impact On VAZALORE effect is about high. to the saw force quarter share between year fourth the campaign new loss of million indicates in nearly per prior net loss driving TV million TV the click end $XX we for and with next $X.X for will consumer of buy and $X.XX of million $XX.X ratio the plan. VAZALORE per with TV. of driving advertising And, strong they very

basis, non-GAAP loss or Our share per On share was change our $XX.X net diluted to the in fair price. prior the year the a share of warrant compared per million period. non-GAAP GAAP loss stock the $X.XX, and to to in of loss fluctuation related reported the loss company’s our due liability adjusted basic net non-cash value includes per in adjusted net $X.XX $X.XX an of

the value dividends not fair You net may net to, useful conversion loss results adjusted in liability, the analysts a and net financial statements to adjusted GAAP should an preferred be considered per to non-GAAP addition unaffected lieu under REG-G loss of provide beneficial net volatility and by measures non-GAAP added operating but of the and we non-cash reported in and impact per loss our the stock or feature. of non-GAAP reconcile have table This with investors of in share that number. was Adjusted addition loss change the to EPS of GAAP. noticed warrant share

no compared the with of of a now higher of balance We some balance to items. proceeds have million, sheet. common debt on of due the receipts of $X.X Turning of million, quarter XX, with net our VAZALORE coupled performance distribution exercises execution million quarter initial agreement issuance our cash and $X.X continue warrant of sales cash of or $X.X of in third the sheet initial our from primarily plans. from cash demonstrates to the ended $XX.X as and launch balance VAZALORE under summary, our stock agility our focused received to In equity to we phase million $XX million and sequentially ATM June

and into launch is market awareness on turn the team phase I drives track call Our With our to further of that, Natasha? will brand next Natasha. the back and poised penetration. over and

you, Thank Rita.

increasing these online to by seen, purchases it. XXX reviews reviews. highly invention as a evidenced I highlight continued as positive by overwhelming milligrams We milligrams, few long and XX for this receive overdue. of we’ve is some recommend well week-over-week feedbacks both consumers as that from consumer To

minor provides dose best on Easy So and pain. swallow best arthritis the low far my the aspirin relief for market. to

aspirin aspirin are a they have aspirin that themselves are over only to physicians is about patients already more pills. are encouraging healthcare ask to new in therapy. capsules degree category is or We formulation that often consumers, also about of care avoiding new, They managed We’ve hearing -the-counter this for aspirin. a the even with also reaching that have thus a that interest are release interested of patients the new reference for VAZALORE swallow immediate also and in the regarding issues Physicians bioequivalents the not the also but swallowing seen made released their information easy innovative to Professionals who tolerate professional process. aspirin. from form that cannot available to commercial experiencing pleased high TV

access the hospitals and Our calls in The healthcare to are practices, person awareness cardiovascular professionals heart in the being calls field targeted by per in larger with top-XXX gaining force averaging is affiliated our majority country. eight stroke the of made group day. building

duration accessing of short network, patients. of In the HCPs reach response already the expand In their in fact, care them and samples they’ve include to our their therapy XX% expressed in and to to to intend a field, second they in appropriate targeted of coupons and targeted aspirin the we the top very strategy, of cardiologists being have to reached all continuing alternative phase launch referral positive VAZALORE. of sites distribute

VAZALORE Electronic VAZALORE are HCPs their along process on with their also now platforms that other the patients, listed facilitate EMR is We to help excited for see Medical to to secondary for Record, recommend prescribed medications. prevention

our coupon expanding publications, healthcare continuing to scientific advancing with through promotional our with and hospital-based aspirin science with and and in broad email a outreach pharmacists further our We education commitments implemented information continue and partnership conferences, campaign and surrounding stained We’ve and medical events. advisory retail medical kits board communication alerts therapy education medical for the professionals incentives. including deep

The last the a dose Cardiovascular XX study. study dose randomized, by XXX preliminary of Angiolillo data milligram the publication Meeting parameters the showed were doctors was and and consistent to with absorption VAZALORE previous crossover Franke, the in week or the a during included fast, study investigate pharmacologic VAZALORE of published TCT and of and of the and milligram was Florida, PD with XX results findings pharmacokinetic University a PK Cardiovascular results was Our in the reliable plan and conducted studies expected, Florida. as pharmacodynamic after poster single milligrams. VAZALORE Research which the open-label, provided first virtual This presentation from Therapeutics our Orlando from includes led Transcatheter Foundation recently

studies approved that about excited of aspirin VAZALORE the additional and these VAZALORE beyond supported XX first VAZALORE are our provide milligram capsules approval that the clinical We XXX milligram. filled liquid findings FDA information

take of of of a conference posted presented pertains use aspirin clot-related use event have I’d the to aspirin PSTS TCT, issued discuss on interview a data The currently media The guidelines and cardiovascular cardiovascular and disease. and further live clinicaltrialresults.org. primary recommendations draft US recommended cardiology based a the the Gibson those to event already in at world-renowned cardiologist, interview Dr. do their heart such pertain Preventative a cardiovascular the who at Taskforce regarding confusion or address on to broadcast doctor’s U.S. stroke had not prevention a are aspirin attack by taking the as for on in the Additionally, Angiolillo to to moment first or held was VAZALORE with interventional is to community. like U.S. PSTS Dr. scientific the the Services recent a the recommendation.

patients a VAZALORE’s therapy disease help with a a and to targeted of reminder, or As already attack history who cardiovascular another those is stroke. population on are aspirin clot-related physician heart prescribed prevent

recommend patients limit a secondary prescribed heart continue a by ago, followed state is the their delivery Several their are prevention practice to cardiovascular and of part its the of of patients, recommendations Heart cardiologists As designed plan the system to following secondary American foundational of aspirin their Cardiology for help clot-related prevention stroke. unique updated years establish aspirin for daily as stomach. Millions College or aspirin recommendations protect which new people option disease. with of VAZALORE the Association to and aspirin use in the established is American attack stroke. heart physician take therapy closely attack a an clot-related Their cardiologists that or without

held aspirin. the physician and In Should products. enteric Townhome life-saving to You against addition, of health also targeted therapy. service though the clarify October aspirin VAZALORE Stop of VAZALORE plain contact cardiovascular technology of we to delivered the secondary public advice from attempt plus the a our Ask pharmaceutical disease. role a with aspirin of stop therapy coated to stretched delivery other laser-focused of of They together a believe asking next stomach. as which continued inside medical ingredients. drug now because quarter, Last issues aspirin aspirin patients capsule phase Your PLxGuard drug in leaders limiting differently and XX Meeting reported clinicaltrialsresults.org. strongly the complex the many reliable, importance discontinuing clarify got The This Aspirin? its the of gastrointestinal on meeting also VAZALORE a many Start on help stomach release special issues. history direct to posted aspirin announced or for aspirin patients townhome virtual absorption on prevention an launch. value Doctor start for whether cardiovascular fast, delivers titled, is pain on platform in are we platform, the or the benefits of of delivery be applicable active the may We and develop In plans with relief to confusion, allows the critical PLxGuard

our VAZALORE see PLx assess represents will in progress ongoing describing a technology for candidates platform now platform, of our product as and evolution launch our and we growth drug company. As delivery you plans. are PLxGuard we That the

that for tuned more stay year. next information on So

household name for you such to As mission open and and that, Neurontin, instructions. with launched knows a aspirin a Zyrtec LIPITOR, and several to will VAZALORE the products of This making is I much the PLx the just has Operator, management benefits a build know, With questions. providing team on team the well-known as of for needed patients. few. Mucinex, megabrands go call to management how please Zantac, millions name ahead Claritin

Gershell [Operator from Oppenheimer. with Instructions] question First is Leland

Your question please.

not until help given and the with we could for now down about progress my the in launch. is stocking, Year. just reorders you and after want obviously the QX out were questions VAZALORE and on congratulations New Thank the see, inventories morning. QX, the occur kind to taking thrust may Good think perhaps great initial I it robust gates us that sales in of of if

SPSTF general. the potentially had some quarter, recommendations the well, impact which have fourth course, of aspirin on come the as of have sales We in through beginning also may of at

of without guidance help about we Thank think If how about course, us the QX in maybe you QX. versus should numbers giving think you. could

Rita. Leland, it’s Hey,

with it’s displays So, distribution, extensive out typical all on three of as as only there you other store. had of said, tens also we experience not were so, quite know, phasing initial stock-ins, SKUs the thousands all you shelves there places shelves, with drugs, our with on in in

we’ve past, is most OTC in as whenever you brand, it especially experienced important. on want, So, shelf getting the an the

the Phase are significant as are out, fourth in that So, and Phase quarter. we terms roll activities we entering this of in X was now in so seeing X promotional

to are the have So, the going reorders quarter we fourth activities we lot then, quarter. much in larger in anticipate first rush through and those holiday a of than the

are can you retailers go and season. to imagine, the As the all for stocked ready holiday

once and turns health to it in So, February. is thinking they to New going in are health start the Year, particular heart their about really centered

So, I that quarter next fourth does would in the quarter. really Hope, more reorders look of phase than the help? to the first

able your to-date? to you of that’s Are comment than Yes. split level any happened reordering

that’s to Really tell. too early

data and we’ve consumption We years have I showing which in mentioned think growing been I the a last strong of double-digits, couple fantastic. that is

now, right plan levels start inventory going getting are their watch reorders. their to into end they So, and to of year, the the really

margin my the And just gross question margins. helpful. That’s last – then, Okay. on

You improvement process. just this had look a you XX%. How that scale the also meaningful there? should Is Thank manufacturing XXXX we you. optimize think further as through improving and potentially about with to

XXX have sizes. that much hoping - we obvious are lower meaningful improvement. much we reasons. It’s Yes, smaller four batch times and is it’s for fill the it’s margin The

will Scientific working Fisher are be Thermo and first XXX. our However, with we capacity to Cincinnati up in partner expand

a quite and we the equipment in can XXX. in of investing are plants, throughput so capacity on their bit We the improve that

Leland. maybe look year to would that I post-launch, So, one

think it initial line improving some up the as running it’s now imagine also you we some on So, could had to those and improve be, – that, we are towards margins. not would but working back I veins efficiently as as

to and Terrific. again, progress. on very much hear all Thanks the glad

you, Thank Leland.

you, Thank Leland.

James. Our comes Raymond from next question Elliot with Wilbur

Your question please.

tears the of on are Thanks. to Good know, of when management doing never and break in they be I don’t to order, of but morning. blood supposed is even I analyst I teams what – the we heavy rules an of this revenue in but a I we maybe lot congratulations before in caught know that’s congratulate doing think terms being that, initial sweat to there terms shared got on I order point. few a recognition.

So, congratulations.

Rita. for actually is question First

follow-up questions of we you Just, margin expect early want think on peak. the at just on to move the you and So as where about to sort I trends will ultimately gross be

in for is would just I XXX margin improving to terms to the terms initial the couponing some things I is you that, the small am the gross and I relatively versus the XXX promotions all couple of is net that then. optimizing growth. not you maybe double-digit guess and are metrics mentioned the trying in volumes. overall Just the things, it in a in profile that how margin impacting scheme important And Follow-up are fact. probably of ascertain of formulation other grand correct now tracking showing of and mean, Rita, of the but times you on right that

curious the metrics to are that from from more coming Just that feedback just us direct those or the available third-party retailers? are is outside

Well, feedback Yes, last our actually I question take direct that’s retailers. the from first.

get we some the retailers. performance some So, of top from

that’s used to able inventories with So, them. are to plan be we

So there are that not data. to buy that able metric we unfortunately, and same is

the with And have getting gross back to margins. to you you. for to share me So, wait it

one post two gross So, parts for launch of I sales to One all will improve, yes, hopefully is which there margin. significantly so, mentioned. the the obviously, reasons is cost year

gross one The that one is you mentioned, other is net. as to the well

any dropped. increase redemptions a with We when have launch, estimated we coupon So, imagine as you actually couponing. can are in record significant they

we to have out going the professionals. coupons healthcare So

We have our and for We really them have trial website. displays actually our on VAZALORE. to drive them on

to it’s So important an item have.

can product. So our that they try

is to would than you imagine. run, initial more net the there So, yes, so, in gross

and as also increase activities So, improve we both we hold. well revenue, hope really of these our margin proceed lines as as to impacting gross and take is that those promotional

this for out not question a yet, And Thanks. of have myself. Okay. you forget we both and then

it may an terms some may the KOLs aspirin on ultimately activity pad sure obviously, I filled product. as out presume that going uptake. volatile of kind initial short-term of and be engaging the and of So, be using what and I for front patient a are and with lot your a fact an thoughts trying comes pharmacy of a hopefully, a I think obviously physicians data as seeing the initial though even the answer just VAZALORE a point, pad of like is they am But the presents of there on mean, about I or you to maybe this. thinking Over-The-Counter in targeted with just of in some it’s to prescription about in lot away prescription it at seems out could heard I sort back But that to versus am CSO up on if prescriptions physician the idea. that correct. And for of door. prescriptions, as curious that not get VAZALORE have in sort that show patients. is your guys

Yes. take Elliot. that I’ll

ago few the One on of the things record about every a medical we fact that now electronic platforms. talked moments is is VAZALORE that

That it in PA that a for find professional nurse list. it’s to practitioner or healthcare on a the databases. easier all or a dropdown So, whether physician a VAZALORE it’s makes

to front there count in have gets some is for And shelf. be the to launch. I patient pharmacy to But the it. lion business Rxs it it to make our that, will get yes share hand pharmacy. how designed directional as store. will and also So will The that’s potentially when easier be the goes in for going from the escribed the and are see to wouldn’t of adjudicated, consumer that in on the doing it we of The but

true shelf are we the data the where purchased growth Our consumption is week-on-week. are coming product our that’s data And off being consumers. by that seeing

after here where So, we’ve in before brands confident months what’s exactly are really being is we we are. as important the these of market, built on two-and-a-half that,

are We we be. where should

accelerate are growth months activities that near-term will and that We all and few ago continuing mentioned that both sales. the near-term a I that Rita

then, when likely thought of coming out there noise a marketplace. in doctors see sort of curious does what wake window seem a utilization It bit. USPSTF than you’ve Thanks. more looks seems therapy just terms you, of heard a there the last of if the has back Okay. potentially there does in And ago guidelines. of some or you and sort of is Obviously, in of that. seem point this back wake of a get noise markets, impact. is Natasha, the stepping earlier lot in the wondering actually on guidelines mean, an doesn’t just maybe the lot But of opportunity therapy opening years but And real comments there otherwise. little question in just noise your maybe to Thanks. of created patients of that be has were time going the for guidelines world off been kind just of in I some you a and the impact or clear about financial but an like Actually, to X% terms it trends. dipped seem I confusion at to of the frankly sort for really be like, it kind of of pretty to

disease Yes. Thanks secondary invasive to vascular prevention community a an Elliot. cardiology every It confirm a opportunity There about It’s of I in is and is is once absolutely the patient procedure commercial stroke. on and is had an mean, that’s in attack aspirin important how debate no heart again or a our aspirin guidelines. foundational. strategy.

there it an And so, is opportunity.

because aspirin of why are rest attack. are is Over for their you product. talk risk others. aspirin. data that when to more its Those actually from and cardiology townhome few their and There leaders, patients stop risk programs a require having Angiolillo heart touchpoints by therapy and with and supporting Gibson much upset a the potentially out And lot XX% Dr. an together lives we of multiple in they community patients that’s these of as As different coming important put the at there and off company themselves is the as an patients. aspirin taking a thought a held cardiology are was aspirin significant use Dr. the community like of for confused that

yes, opportunity and confirms So, it it I our our community, confirms and opportunity an strategy to that it’s have the grow. think shareholders for the and we investor

where million space, of form in focused XX and new in tactics where that’s of people country the that’s lies our space over HCP are with that have focus retailers. aspirin both consumer a all and the this use could partnerships We and in our our

Alright.

[Operator is am question I from sorry. next Jason Our comes Butler next Securities. with Instructions] – JMP Our question

question Your please.

Hi. Thanks the taking question.

add the me start to the on launch. congrats my great Let

guess, I the that you are bit try real terms hearing, way feedback, are of a of VAZALORE. of the to direction gates? product? in out then, in that their the got you you are reaffirms little the patient of can that physicians that consumer cost up, is anything hearing starting How actually evidence the physician process world talk about finding patients terms the on Thanks. products or to And working the feedback right Just price you on pricing the more

take I’ll the Yes. consumer first.

aspirin about continue the this enteric FDA’s and particular and And has but market also is the absorption patient, and to is what are brands with a GI And studies company, product patient, has is way It hearing addition a aspirin. a studies we category new of that are in dominating words published is, and and what’s our not over which reliable understand We we, aspirins no important as research. invest really VAZALORE of aspirin. is on other by market of listen think market are how new the seeing consistent secondary this so it radic because important and if only the helping category. But to predictable because terms now. really we of years delivers listen glowing. patient the needy to you been to for that clinical describe a And the we very needs for launched that’s we’ve coated form reviews the a important in The yes, premium it’s the to the many as big online us, decades. what There for innovation price prevention in. that benefit, an own the in form in our is that

that becomes interesting behind VAZALORE, the very So, professional the the the really respected. understand understandable is when the we’ve to and consumer then What learned consumer is and price healthcare benefit us. feedback

As on as aspirin board the just cardiologists HCP the important. doing group concerned, frankly, it’s is for is It’s always have far its job. assumed patients. know They of that these

to very about And form are work. aspirin so, in them talk how when new does works. of it How a interested the technology we they

to about Over-The-Counter XX lot not which methods matter why a communication, And as patterns lot of communication, composition consumer the an has is mechanism of the to way methods product medical so, but education, communication only is by VAZALORE the and our of also make all our reason and a of delivery, the treat. global

signaling well. all are markets those successful to X.X all launch. we exactly So, building know we this in a want into in months that’s markers brand where be We of terms the of

the both We continue HCPs, the and and to to into activities. coming the from that listen are doctors, we consumer the the incorporating our pharmacist feedback

we to are that. able small company, do a As

flexible. are We

agile. We are

means have as we We the weeks. next our resources over these and applying and the are the few tactics we speak into learnings

Thanks the for Thanks, Natasha. helpful. That’s questions. taking

Thank you.

Thank you, Jason.

you. remarks. will to for turn call Natasha the back I Thank her And final

PLx our you we launch know time Thank and how we closing, management blueprint executing a team, proven plan successful are you, for to this strategy building Carmen. brand. In Thank launch products this your our for and morning. with

day. a update. next Have our to forward Looking great

that, Thank And you now end may thank disconnect. we you with for you. And today. participating. We program for our